Thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma: Relationship between histological parameters and chemosensitivity to 5-fluorouracil

European Urology

Volumn 43, Issue 1, 2003, Pages 45-52

  Hirano, Yasuhiro ^a   Takayama, Tatsuya ^a   Kageyama, Shinji ^a   Ushiyama, Tomomi ^a   Suzuki, Kazuo ^a   Fujita, Kimio ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil; Dihydropyrimidine dehydrogenase; Renal cell carcinoma; Thymidine phosphorylase

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; THYMIDINE PHOSPHORYLASE;

ARTICLE; CANCER GRADING; CARCINOGENESIS; CHEMOSENSITIVITY; CORRELATION ANALYSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0037246688     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00498-0     Document Type: Article

References (21)

1. Hartmann KU, Heidelberger C. Studies on fluorinated pyrimidines. J Biol Chem 1961;236:3006-13.
2. Ishikawa F, Miyazono K, Hellman U, Drexler M, Wernstedt C, Hagiwara K, et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989;338:557-62.
3. Imazono Y, Takebayashi Y, Nishiyama K, Akiba S, Miyadera K, Yamada Y, et al. Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma. J Clin Oncol 1997;15:2570-8.
4. Marchetti S, Chazal M, Dubreuil A, Fischel JL, Etienne MC, Milano G. Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis. Br J Cancer 2001;85: 439-45.
5. Hirano Y, Kageyama S, Ushiyama T, Suzuki K, Fujita K. Thymidine phosphorylase activity in transitional cell cancer: Relation to histological parameters and chemosensitivity to fluorouracil-related drugs. Anticancer Res 2000;20:4315-8.
6. Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renee N, et al. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995;13:1663-70.
7. McLeod HL, Sludden J, Murray GI, Keenan RA, Davidson AI, Park K, et al. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumors. Br J Cancer 1998;77:461-5.
8. Guimbaud R, Guichard S, Dusseau C, Lochon I, Bugat R, Chatelut E, et al. Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humans. Cancer Chemother Pharmacol 2000;45:477-82.
9. Uetake H, Ichikawa W, Takechi T, Fukushima M, Nihei Z, Sugihara K. Relationship between intratumoral dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer. Clin Cancer Res 1999;5:2836-9.
10. Mizutani Y, Wada H, Fukushima M, Yoshida O, Ukimura O, Kawauchi A, et al. The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer. Eur J Cancer 2001;37: 569-75.
11. Lowry OH, Rosebroough NJ, Farr AC, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193:265-75.
12. Naguib FMN, El Kouni MH, Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 1985;45:5405-12.
13. Ikenaka K, Shirasaka T, Kitano S, Fujii S. Effect of uracil on metabolism of 5-fluorouracil in vitro. Gann 1979;70:355-9.
14. Hirano Y, Ushiyama T, Suzuki K, Fujita K. Clinical application of in vitro chemosensitivity test with the histoculture drug response assay for urological cancers: wide distribution of inhibition rates in bladder cancer and renal cell cancer. Urol Res 1999;27:483-8.
15. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, et al. Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil. Jpn J Cancer Res 2000;91:105-12.
16. Morita T, Matsuzaki A, Tokue A. Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA. Int J Cancer 2001;92:451-6.
17. Yogoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma. Semin Oncol 1995;22:42-6.
18. Schwartz EL, Baptiste N, Wader S, Makower D. Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil. J Biol Chem 1995;270:19073-7.
19. Gebrosky PN, Koukol S, Nseyo OU, Caroenter C, Lamm LD. Treatment of renal cell carcinoma with 5-fluorouracil and alpha-interferon. Urology 1997;50:863-8.
20. Milano G, Fischel JL, Etienne MC. Inhibition dihydropyrimidine dehydrogenase by α-interferon: experimental data on human tumor cell lines. Cancer Chemother Pharmacol 1994;34:147-52.
21. Mizutani Y, Nakanishi H, Yoshida O, Fukushima M, Bonavida B, Miki T. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer 2002;38:167-76.